Volume 21, Number 11—November 2015
Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014
Highlight and copy the desired format.
|EID||Feikin DR, Alraddadi BM, Qutub M, Shabouni O, Curns A, Oboho IK, et al. Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. Emerg Infect Dis. 2015;21(11):2029-2035. https://dx.doi.org/10.3201/eid2111.150764|
|AMA||Feikin DR, Alraddadi BM, Qutub M, et al. Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. Emerging Infectious Diseases. 2015;21(11):2029-2035. doi:10.3201/eid2111.150764.|
|APA||Feikin, D. R., Alraddadi, B. M., Qutub, M., Shabouni, O., Curns, A., Oboho, I. K....Madani, T. A. (2015). Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. Emerging Infectious Diseases, 21(11), 2029-2035. https://dx.doi.org/10.3201/eid2111.150764.|
Middle East respiratory syndrome coronavirus (MERS-CoV) causes a spectrum of illness. We evaluated whether cycle threshold (Ct) values (which are inversely related to virus load) were associated with clinical severity in patients from Saudi Arabia whose nasopharyngeal specimens tested positive for this virus by real-time reverse transcription PCR. Among 102 patients, median Ct of 31.0 for the upstream of the E gene target for 41 (40%) patients who died was significantly lower than the median of 33.0 for 61 survivors (p = 0.0087). In multivariable regression analyses, risk factors for death were age >60 years), underlying illness, and decreasing Ct for each 1-point decrease in Ct). Results were similar for a composite severe outcome (death and/or intensive care unit admission). More data are needed to determine whether modulation of virus load by therapeutic agents affects clinical outcomes.
Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported in September 2012 in a patient from the Kingdom of Saudi Arabian (KSA) who had pneumonia (1). From September 20, 2012 through January 2, 2015, a total of 825 MERS-CoV cases (356 fatal) have been reported from KSA, representing most of the cases worldwide (2,3). Initial reports of clinical course among MERS-CoV patients from KSA indicated high case-fatality rates (>50%) (4,5), but the subsequent increase in testing of symptomatic and asymptomatic persons as part of contact investigations has shown that approximately one fifth to one fourth of patients are mildly symptomatic or asymptomatic (6,7).
The factors dictating severity of illness and outcome among MERS-CoV patients are still not well defined. Underlying illness and older age have been associated with more severe disease and death (4,5,8,9). In some other viral respiratory illnesses, the amount of virus measured in the respiratory tract has been associated with more severe disease (10–16). However, whether virus load of MERS-CoV is associated with severity of illness is unknown. We evaluated this association among a large cohort of MERS-CoV patients from the Jeddah region of KSA during 2014.
Eligible persons were children and adults admitted to Jeddah area hospitals during March–May 2014. Patients were included if they met the following criteria: 1) tested positive for MERS-CoV by real-time reverse transcription PCR (RT-PCR) from nasopharyngeal swab, sputum, or bronchoalveolar lavage samples at the Jeddah Regional Laboratory during March 26–May 16, 2014, and 2) were matched to a line list of Jeddah MERS-CoV patients with the most complete clinical and outcome data (17)
Jeddah Regional Laboratory maintained a database of all patients tested that included cycle threshold (Ct) values for the upstream of the envelope E (upE) gene and open reading frame (ORF) 1a targets. A composite of MERS-CoV patients for whom medical history and clinical information were obtained by case report forms and medical records review or by phone calls was compiled in late May 2014 (17). Laboratory and clinical datasets were linked by matching the national identification number for Saudis or foreign identification number for foreigners. If this number was a close but not exact match, confirmatory evidence of identity included sex, age, and date of specimen collection. All personal identifiers, including identification numbers, were stripped from the merged, analytic dataset.
Specimen Collection and Laboratory Testing
Patients with suspected MERS-CoV infection were tested as soon as possible after admission to Jeddah area hospitals at the discretion of the treating clinicians, under guidance from the KSA Ministry of Health (MOH) (18). In addition, some close contacts of confirmed MERS-CoV patients and health care workers who cared for MERS-CoV patients were sampled as part of contact investigations. KSA MOH guidelines recommended collection of nasopharyngeal swab as the screening specimen for all patients suspected to have MERS-CoV but enabled additional collection of lower respiratory tract specimens for intubated patients (5,18). Swab samples were obtained by using Dacron flocked swabs and placed in 2–3 mL of virus transport media. Specimens were stored at 2°C–8°C and transported to the Jeddah Regional Laboratory within 48 hours after collection.
At the Jeddah Regional Laboratory, total nucleic acid extraction from clinical specimens was performed by using the MagNA Pure LC 96 or the MagNA Pure Compact (Roche, Basel, Switzerland). Both instruments were programmed for the DNA_Blood_100_400_V3_2 protocol (Roche) with a 200-μL sample volume and 100-μL elution volume. Real-time RT-PCR amplification was performed by using the ModularDx Coronavirus SA1 (EMC) upstream E-gene kit (TIB Molbiol LLC, Berlin, Germany) for primary detection, and the ModularDx MERS-Coronavirus (EMC) ORF1a kit (TIB Molbiol LLC) was used to confirm positive results (5,19). Discordant results needed to be confirmed with a second clinical specimen. Ct values were read as positive if the amplification curve crossed the threshold set above the background fluorescence levels. Standard curves were not generated for each real-time RT-PCR run, and absolute virus concentrations in the specimens were not calculated. Because upE and ORF1a Ct values were highly correlated (Spearman’s ρ) and because the upE region is noncoding and would be less influenced by the presence of mRNA, all primary analyses were run for upE Ct values.
Outcome and Risk Factor Variables
The main outcome of interest for this study was severity of illness and the main predictor being assessed was the MERS-CoV virus load, as reflected by the Ct values. The following severity outcomes were assessed: death by the time of follow-up chart review or phone contact, a composite severe outcome (death and/or admission to the intensive care unit [ICU]), admission to ICU versus admission to the general ward among hospitalized patients, and symptomatic versus asymptomatic infection among surviving patients. Other independent variables in the analysis as risk factors and/or potential confounders of the association between Ct value and outcome were underlying illness, age, sex, and week of specimen collection.
Ct values were used as a relative indicator of virus load, in that lower Ct values were considered to reflect higher virus load than were higher Ct values, an intrinsic characteristic of real-time RT-PCR (12,20). Analysis of the association between Ct values and severity was restricted to nasopharyngeal specimens because Ct values from lower respiratory tract specimens (e.g., sputum and bronchoalveolar lavage) can be lower (i.e., higher virus load) than upper respiratory tract specimens, thereby introducing a possible bias when evaluating severity (20). If multiple specimens were available for a patient, the nasopharyngeal sample with the earliest date of collection was used.
Underlying illness was defined as heart disease, chronic lung disease, renal diseases, and/or diabetes. Age was divided into quartiles based on the age distribution of MERS-CoV–positive patients. To assess whether changes might have occurred over time during the period of testing that confounded the results (e.g., specimen collection or transport methods), we created a categorical variable based on the date of specimen collection for each 2-week period during March 26–May 16. “Days since illness onset” was the difference in the date of the first symptom of MERS (i.e., cough, dyspnea, fever) and the date of specimen collection.
Because Ct distributions were not normally distributed, we compared the Ct values between 2 groups using the Wilcoxon rank sum test and for >3 groups using the Kruskal-Wallis test. Ct values also were grouped into high virus load (Ct≤26), medium virus load (Ct 27–33), and low virus load (Ct≥34) values for categorical analysis, and groups were compared by using the χ2 test (Brett Whittaker, pers. comm. on grouping of Ct values). Correlation between other continuous variables and Ct values were compared after the values were ranked and were assessed by Spearman rank correlation coefficient (Spearman’s ρ).
Univariate and multivariate logistic regression was performed to identify risk factors for death, as well as for a composite severe outcome (death and/or ICU admission) among MERS-CoV–positive patients. Categorical variables with missing data were coded to include missing as a valid response category.
Variables with p<0.10 in univariate analysis were included in multivariable analyses, and backward and forward selection methods were performed to identify significant variables at p<0.05 for any category of each variable. The main focus was to determine whether the outcome of interest (i.e., death or composite severe outcome) was more likely as Ct values decreased (i.e., virus load increased). A variable was considered to be a significant confounder of the Ct association if the parameter estimate for Ct changed by >10% and was included in the model regardless of statistical significance. Separate analyses were run for the Ct values resulting from the upE and ORF1a RT-PCR targets. All analyses were performed by using SAS 9.3 (SAS Institute, Cary NC, USA). No formal sample size was calculated; rather, all eligible patients during the study period were included in the analysis.
During the study period, the clinical and laboratory datasets for 120 (50%) of 239 MERS-CoV–positive patients were able to be linked. Seventy-three percent were men, and the median age of all patients was 50 years (range 8–86 years); for 19 patients, information about age was missing. Thirty-two (26%) patients were health care workers, and 65 (56%) were Saudi. Specimens for MERS-CoV were collected in 18 facilities; 59% of specimens were collected from 4 facilities, and the remaining 14 facilities provided <5 samples each. In addition, 15 (13%) specimens were collected at home for asymptomatic or mildly symptomatic contacts.
Mean and median Ct values for the 120 linked MERS-CoV–positive patients for upE were 30.7 and 32.0, respectively (range 15–37). For 118 patients for whom ORF1a results were available, mean and median Ct values were 30.8 and 32.0, respectively (range 15–37). The correlation between upE and ORF1a Ct values was high (r = 0.94, p<0.001, Spearman’s ρ). The median Ct for the upE target from 106 nasopharyngeal swab samples was 32.0; from 8 sputum samples, 24.5; and from 6 bronchoalveolar lavage samples, was 24.5 (p<0.001, Kruskal-Wallis test) (Figure 1). When restricted to hospitalized patients, the median Ct values for nasopharyngeal swab, sputum, and bronchoalveolar lavage samples were 31.0, 25.0, and 26.0, respectively (p<0.001, Kruskal-Wallis test).
The remaining analysis is restricted to the 102 patients with nasopharyngeal swab samples and known outcome status. Of these 102 patients, 41 (40%) died. The Ct values for the upE target for 41 patients who died were significantly lower than those for 61 patients who survived (medians 31.0 and 33.0, respectively, p = 0.009, Wilcoxon rank sum test) (Figure 2, panel A). Using the composite severity variable, we categorized 48 (47%) illnesses as severe; for these patients, Ct values were significantly lower than for the 54 patients without severe disease (medians 31.0 and 33.0, respectively, p<0.0036, Wilcoxon rank sum test) (Figure 2, panel b). Sixty-seven (66%) patients were hospitalized. Ct values were significantly lower for the 36 hospitalized patients admitted to the ICU than for the 31 hospitalized patients admitted the general ward (medians 29.5 and 32.0, respectively, p = 0.014, Wilcoxon rank sum test) (Figure 2, panel C). Of the 61 patients who survived, Ct values were not significantly lower for the 30 symptomatic patients than they were for the 31 mildly symptomatic or asymptomatic patients (medians 32.0 and 34.0, respectively, p = 0.08, Wilcoxon rank sum test) (Figure 2, panel D). We found similar associations when we categorized Ct values as low, medium, and high (Table 1). The findings were similar for ORF1a (data not shown).
Age was not associated with Ct when assessed either as a continuous variable (r = −0.07, p = 0.48 Spearman’s ρ) or as quartiles (p = 0.91, Kruskal-Wallis test). Of the 73 patients for whom information was available on days from illness onset to swab sample collection, we found correlation between the days since onset and Ct as continuous variables (r = 0.26, p = 0.029, Spearman’s ρ) (Figure 3) with higher virus load found earlier in the course of illness. Among patients for whom the presence (52 patients) or absence (16 patients) of underlying illness was noted, the Ct values did not differ significantly (medians 31.5 and 31.0, respectively, p = 0.48, Wilcoxon rank sum test). For only 13 surviving hospitalized patients was enough information available to calculate the length of hospital stay (median 7 days), and Ct and length of stay were not correlated for these patients (r = −0.02, p = 0.94, Spearman’s ρ). Ct values did not differ significantly by hospital in which the sample was collected (p = 0.33, Kruskal-Wallis test).
In univariate logistic regression, increased probability of death was predicted by older age, presence of underlying illness, and lower Ct (Table 2). In multivariable analysis, being >60 years of age (odds ratio [OR] 11.7, 95% CI 2.00–67.9) and having an underlying illness (OR 5.19, 95% CI 1.08–25) were the strongest predictors of death. Lower Ct values remained predictive of death when adjusted for age and presence of underlying illness; the odds of death increased 17% for each 1 point drop in Ct (OR 1.17, 95% CI 1.01–1.35). For the composite severe outcome, the same factors were identified in univariate and multivariate analysis; Ct was borderline significant (OR 1.16, 95% CI 1.00–1.34) when adjusted for age and underlying illness (Table 2). We found similar regression results with ORF1a– when we adjusted for underlying illness and age with a positive association between lower ORF1a Ct values and death (OR 1.21, 95% CI 1.04–1.40) and severe disease (OR 1.19, 95% CI 1.01–1.40).
We found an association between higher virus load of MERS-CoV detected in the upper respiratory tract, as indicated by lower Ct values, and worse clinical outcome, including death and admission to the ICU. This finding is derived from a large number of MERS-CoV patients from KSA during the upsurge in cases during spring 2014, when MERS-CoV was diagnosed in patients with a spectrum of clinical illness (17). Our findings did not change when we adjusted for other risk factors for severe outcome and potential confounders. Although the exact pathophysiology of MERS-CoV infection in the lung is still unknown, more virions could lead to worse lung damage either by direct destruction of respiratory epithelial cells or by triggering a more vigorous inflammatory response (21). In severe acute respiratory syndrome coronavirus infections, a similar association was observed between worse outcome and higher virus load, as measured in nasopharyngeal, serum, and fecal samples (22). Why some patients have higher MERS-CoV virus load is unclear. Virus load might be related to the inoculum size at the time of infection; anecdotally, primary MERS-CoV infections, which are probably more likely to be acquired from environmental exposure (e.g., camels) than from person-to-person spread, tend to have worse outcomes, even among younger patients, although this factor could reflect other risks or case ascertainment bias (23,24). Virus load might also be related to host factors, such as the immune response to the virus, which in turn could be affected by intrinsic factors, such as the presence of underlying illness or host genetics.
This association between outcome and virus load in the upper respiratory tract has been demonstrated previously for other viral infections. Children with higher respiratory syncytial virus loads are more likely to be hospitalized and require mechanical ventilation (10,12,15). Some studies have found higher virus load for influenza viruses among patients who were sicker (14,25). Higher virus loads of human bocavirus in nasopharyngeal aspirate samples were associated with greater severity of illness among Chinese children (16). Other studies, however, have not shown an association between virus load and illness severity (11–13).
Clearly the specimen type can affect virus load. A previous study from KSA showed that median Ct values were lower for MERS-CoV from tracheal aspirate and bronchoaveolar lavage samples than for nasopharyngeal swab samples, presumably reflecting higher virus load in the lower respiratory tract (20). Moreover, lower respiratory tract samples, including expectorated sputum, are positive for MERS-CoV when upper respiratory tract samples were negative (26,27). We observed similar findings with bronchoalveolar lavage and sputum yielding higher virus load than nasopharyngeal specimens, although this could have reflected that these specimens were only available from sicker patients or been due to chance with so few bronchoalveolar or sputum specimens.
Because the severity of patients most likely was associated with the available specimen (e.g., only intubated patients have bronchoalveolar lavage), we restricted our analysis to patients with nasopharyngeal swab samples, which is the recommended specimen for initial MERS-CoV diagnosis according to KSA MOH guidelines (18). The clinical implication of measuring virus load in upper respiratory tract specimens for MERS-CoV is not clear because the virus load probably reflects virus replication in the nasopharyngeal epithelial cells. We assumed that virus load in the upper respiratory tract correlated with that in the lung, although this assumption is not known definitively. By limiting the analysis to virus load among bronchoalveolar lavage specimens, we would have been able to more directly compare virus load in the lung with clinical severity; however, too few of these specimens were available to conduct this analysis.
We showed that several other risk factors were associated with death and severe outcome on multivariable analysis. The strongest risk factors were being elderly and having an underlying illness. Although several studies have shown underlying illness to be common among MERS-CoV patients, including those who died, few have quantified the risk for underlying illness in severe outcomes (5,8,28). We showed that the presence of underlying illness elevated the odds of severe outcome or death by 7–8-fold. The higher risk for severe outcomes earlier in the course of the Jeddah outbreak probably was due to the increase in contact tracing as the outbreak progressed in Jeddah, leading to detection of a greater spectrum of clinical MERS-CoV disease later in the outbreak.
Our analysis is subject to several possible limitations. Ct values are a semiquantitative measure of virus load and therefore only reflect relative virus loads. Without reference to a known standard curve for each real-time RT-PCR run, we were not able to assign specific virus load thresholds to severity categories. Run-to-run variability could have existed in Ct–virus load relationships, although the extraction method, real-time RT-PCR, and equipment remained the same throughout this period in the Jeddah Regional Laboratory. If real-time RT-PCR is 100% efficient, a 1-unit change in Ct indicates an ≈2-fold difference in concentration of virus copies, although such conditions are rarely met in real-world practice (12). Ct values have been used in other reports as an indicator of MERS-CoV virus load (20). Second, specimens were collected from multiple hospitals and the home setting for asymptomatic contacts. This could have led to variability in quality of the specimens, and/or handling and shipping practices in getting specimens to the Jeddah Regional Laboratory. However, unless systematic differences were present by site in terms of the severity of illness affecting specimen collection, this variability should have been nondifferential and biased the findings toward the null. Moreover, we observed no difference in the median Ct across hospitals. Third, data for other outcomes indicative of severity of illness were either missing in some patients (e.g., days since onset, length of hospital stay) or not available at all in the current dataset (e.g., mechanical ventilation, oxygen requirements). Fourth, some patients initially identified by the MOH as asymptomatic and not hospitalized did not have medical records for review, and data were collected by phone for these patients; some of these patients were unable to be contacted and so we could not verify the initial data from the MOH, leading to potential misclassification for some variables. Finally, without systematically sampling and testing sequential specimens in the same patient during the course of illness, we are unable to determine the temporal sequence in the association between virus load and outcome, i.e., we cannot determine whether higher virus load causally leads to severe outcomes
Although we present evidence for an epidemiologic association between virus load and severity of MERS-CoV illness, the clinical implications of our findings are unclear. At this time, MERS-CoV has no known treatment, other than supportive care. Several approaches to treatment, including antiviral drugs and immunotherapy are being investigated (29). More data are needed on whether modulation of virus load by therapeutic agents can affect clinical outcomes.
Dr. Feikin is the Epidemiology Branch chief in the Division of Viral Diseases National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. His primary research interest is the epidemiology of pneumonia.
We thank Dean D. Erdman and Brett Whitaker for insightful input into the laboratory testing results. We thank Richard Dunville for assistance with the database management and Huong Pham for help with graphics.
The KSA MOH and the US Centers for Disease Control and Prevention provided funding for this study.
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20.
- Command and Control Center Ministry of Health. Saudi Arabia. Total confirmed cases since June 2012 [cited 2015 Jan 14]. http://www.moh.gov.sa/en/CCC/PressReleases/Pages/Statistics-2015-1-02-001.aspx
- World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)—Jordan. 2015 [cited 2015 Jan 5]. http://www.who.int/csr/don/05-january-2015-mers-jordan/en/
- Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389–97.
- Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752–61 and.
- Centers for Disease Control and Prevention. Updated information on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and guidance for the public, clinicians, and public health authorities, 2012–2013. MMWR Morb Mortal Wkly Rep. 2013;62:793–6 .
- World Health Organization. Global alert and response. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update—as of 9 May 2014 [cited 2014 May 12]. http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1
- Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368:2487–94.
- Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–6.
- Buckingham SC, Bush AJ, DeVincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000;19:113–7.
- Franz A, Adams O, Willems R, Bonzel L, Neuhasen N, Schweizer-Krantz S, Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory tract infections. J Clin Virol. 2010;48:239–45.
- Fuller JA, Njenga MK, Bigogo G, Aura B, Ope MO, Nderitu L, Association of the Ct values of real-time PCR of viral upper respiratory tract infection with clinical severity, Kenya. J Med Virol. 2013;85:924–32.
- Jansen RR, Schinkel J, Dek I, Koekkoek SM, Visser CE, de Jong MD, Quantitation of respiratory viruses in relation to clinical course in children with acute respiratory tract infections. Pediatr Infect Dis J. 2010;29:82–4.
- Lee N, Chan PKS, Hui DSC, Rainer TH, Wong E, Choi KW, Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500.
- Utokaparch S, Marchant D, Gosselink JV, McDonough JE, Thomas EE, Hogg JC, The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr Infect Dis J. 2011;30:e18.
- Zhao B, Yu X, Wang C, Teng Z, Wang C, Shen J, High human bocavirus viral load is associated with disease severity in children under five years of age. PLoS ONE. 2013;8:e62318.
- Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H, Aloraini MS, 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. N Engl J Med. 2015;372:846–54.
- Kingdom of Saudi Arabia Ministry of Health. Case definition and surveillance guidance for MERS-CoV testing in Saudi Arabia—13 May 2014 [cited 2014 Jun 28]. http://www.moh.gov.sa/en/Documents/MoHCaseDefinitionMERSCoVVersionMay132014.pdf
- Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 2012;17:20334 .
- Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis. 2014;210:1590–4.
- Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195:1126–36.
- Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004;10(Suppl):S88–97.
- Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;370:2499–505.
- Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF, Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis. 2014;23:63–8.
- Jansen RR, Wieringa J, Koekkoek SM, Visser CE, Pajkrt D, Molenkamp R, Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol. 2011;49:2631–6.
- Kapoor M, Pringle K, Kumar A, Dearth S, Liu L, Lovchik J, Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) into the United States. Clin Infect Dis. 2014;59:1511–8.
- Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013;13:745–51.
- Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–16.
- World Health Organization. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do [cited 2014 May 12]. http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13.pdf
- Figure 1. Box plot of Ct values for MERS-CoV patients by specimen type, Kingdom of Saudi Arabia, 2014. Box and whiskers plot features are as follows: central line in box is...
- Figure 2. Box plot of Ct values for 102 patients infected with MERS-CoV by severity status. Kingdom of Saudi Arabia, 2014. A) Patients who were alive (n = 61) versus dead...
- Figure 3. Relationship between days since illness onset and upE Ct values for MERS-CoV from nasopharyngeal swabs, Kingdom of Saudi Arabia, 2014. Ct, cycle threshold; MERS-CoV, Middle East respiratory syndrome coronavirus;...
- Table 1. Ct for upE gene based on several indicators of severity of illness for 102 patients infected with MERS-CoV, Kingdom of Saudi Arabia, 2014
- Table 2. Results of logistic regression for risk of death and severe outcome (death or ICU admission) for 102 patients with MERS-CoV infection, Kingdom of Saudi Arabia, 2014
Please use the form below to submit correspondence to the authors or contact them at the following address:
Tariq A. Madani, Department of Medicine, Faculty of Medicine, King Abdulaziz University, PO Box 80215, Jeddah 21589, Saudi Arabia
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: October 16, 2015
- Page last updated: October 16, 2015
- Page last reviewed: October 16, 2015
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)